Trial Profile

A phase I/II theranostic trial, evaluating 61Cu-NuriPro alongside the 67Cu-NuriPro

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copper-61 NuriPro (Primary) ; Copper-67 NU 101 (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

27 May 2026 According to a NUCLIDIUM media release, the company expects to initiate this trial later this year.
10 Jul 2025 According to Angelini Group media release, the company has co-led a CHF79 million Series B financing round in NUCLIDIUM, which will fund the clinical development of NUCLIDIUM's Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications.
25 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com